Lyra Therapeutics Inc (LYRA)

$11.34 -0.51 (-4.30%)
Market Cap 15.03M
Revenue (ttm) 1.53M
Net Income (ttm) -93.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,107.19%
Debt to Equity Ratio 0.00
Volume 219,500
Avg Vol 821,985
Day's Range N/A - N/A
Shares Out 1.33M
Stochastic %K 2%
Beta -0.01
Analysts Hold
Price Target $23.00

Company Profile

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhi...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 393 4600
Address:
480 Arsenal Way, Watertown, United States
joeycash_
joeycash_ Jun. 16 at 3:21 AM
$LYRA
0 · Reply
Ice_Wizard
Ice_Wizard Jun. 15 at 1:23 PM
$LYRA price alert set for 10.90
0 · Reply
MrWick007
MrWick007 Jun. 13 at 4:15 PM
$LYRA can’t find anything g apart from Zack’s upgrade to buy (rank 2) yesterday
1 · Reply
MrWick007
MrWick007 Jun. 13 at 3:58 PM
$LYRA can anyone explain what this is? Insider buy??
1 · Reply
Akbigd
Akbigd Jun. 13 at 3:53 PM
$LYRA reversal Time, If you are on Robinhood. Turn off Stock lending option and force them to cover
0 · Reply
Stmkr
Stmkr Jun. 13 at 3:52 PM
$LYRA Time for reversal again
0 · Reply
Rjinvestments88
Rjinvestments88 Jun. 13 at 3:17 PM
$LYRA nice to see that big order from insider didn't sell 👍
1 · Reply
MrWick007
MrWick007 Jun. 13 at 2:41 PM
$LYRA dead money?
1 · Reply
Stmkr
Stmkr Jun. 13 at 1:42 PM
$LYRA Lets see if management will take the risk of waiting for FDA feedback before raising
1 · Reply
Rjinvestments88
Rjinvestments88 Jun. 13 at 1:13 PM
$LYRA 👀 this Today looking to jump in
0 · Reply
Latest News on LYRA
Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?

Jun 2, 2025, 8:29 AM EDT - 14 days ago

Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

Jun 2, 2025, 7:00 AM EDT - 14 days ago

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025

May 7, 2025, 7:00 AM EDT - 5 weeks ago

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 4:01 PM EDT - 5 weeks ago

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 13, 2025, 4:01 PM EDT - 3 months ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 12, 2024, 4:01 PM EST - 7 months ago

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Oct 15, 2024, 7:00 AM EDT - 8 months ago

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

Sep 27, 2024, 7:00 AM EDT - 9 months ago

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 4:01 PM EDT - 10 months ago

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

May 21, 2024, 9:14 AM EDT - 1 year ago

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

May 6, 2024, 7:59 AM EDT - 1 year ago

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 30, 2024, 4:04 PM EDT - 1 year ago

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

3 'Buy-Rated' Biotech Stocks Under $10

Apr 28, 2024, 4:39 AM EDT - 1 year ago

3 'Buy-Rated' Biotech Stocks Under $10

ADMA GERN

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 26, 2024, 4:51 PM EDT - 1 year ago

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 21, 2024, 4:01 PM EDT - 1 year ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 1, 2024, 4:01 PM EST - 1 year ago

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 4:01 PM EST - 1 year ago

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Lyra Therapeutics to Participate in Upcoming Investor Conferences

Nov 7, 2023, 7:00 AM EST - 1 year ago

Lyra Therapeutics to Participate in Upcoming Investor Conferences

Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer

Oct 16, 2023, 7:00 AM EDT - 1 year ago

Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer

Lyra Therapeutics: Hold For Phase 3 Topline

Oct 10, 2023, 10:56 AM EDT - 1 year ago

Lyra Therapeutics: Hold For Phase 3 Topline

Lyra Therapeutics' Nasal Matrix In Focus: Sniffing Out Opportunity

Oct 9, 2023, 1:20 AM EDT - 1 year ago

Lyra Therapeutics' Nasal Matrix In Focus: Sniffing Out Opportunity

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

Sep 12, 2023, 7:00 AM EDT - 1 year ago

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Aug 29, 2023, 7:00 AM EDT - 1 year ago

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

Jul 13, 2023, 7:30 AM EDT - 2 years ago

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

Lyra Therapeutics: Bob Langer-Founded Company Shows Promising Data For Sinus Treatment

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Lyra Therapeutics: Bob Langer-Founded Company Shows Promising Data For Sinus Treatment

Lyra Therapeutics to Present at Jefferies Healthcare Conference

Jun 2, 2023, 7:30 AM EDT - 2 years ago

Lyra Therapeutics to Present at Jefferies Healthcare Conference

Lyra Therapeutics Announces Closing of $50.0 Million Private Placement

Jun 1, 2023, 7:29 AM EDT - 2 years ago

Lyra Therapeutics Announces Closing of $50.0 Million Private Placement

Lyra Therapeutics Announces $50.0 Million Private Placement

May 26, 2023, 7:57 AM EDT - 2 years ago

Lyra Therapeutics Announces $50.0 Million Private Placement

Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 12, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

May 9, 2023, 4:01 PM EDT - 2 years ago

Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

Apr 25, 2023, 7:59 AM EDT - 2 years ago

Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

Lyra Therapeutics: Negative EV With A Very Compelling Treatment For Chronic Rhinosinusitis In Phase 3

Apr 5, 2023, 9:04 AM EDT - 2 years ago

Lyra Therapeutics: Negative EV With A Very Compelling Treatment For Chronic Rhinosinusitis In Phase 3

Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 29, 2023, 4:06 PM EDT - 2 years ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

Feb 27, 2023, 7:59 AM EST - 2 years ago

Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

Feb 6, 2023, 7:56 AM EST - 2 years ago

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 8, 2022, 4:01 PM EST - 2 years ago

Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study

Sep 13, 2022, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study

LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting

Sep 10, 2022, 8:00 AM EDT - 3 years ago

LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting

Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients

Sep 8, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients

Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022

Sep 6, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting

Aug 29, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting

Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 9, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

Jul 5, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer

Jul 5, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer

Lyra Therapeutics to Present at Upcoming Investor Conferences

May 26, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present at Upcoming Investor Conferences

Lyra Therapeutics: Progress In The Clinic

May 18, 2022, 12:46 PM EDT - 3 years ago

Lyra Therapeutics: Progress In The Clinic

Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 10, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022

Apr 29, 2022, 9:07 AM EDT - 3 years ago

Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022

Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

Apr 25, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

joeycash_
joeycash_ Jun. 16 at 3:21 AM
$LYRA
0 · Reply
Ice_Wizard
Ice_Wizard Jun. 15 at 1:23 PM
$LYRA price alert set for 10.90
0 · Reply
MrWick007
MrWick007 Jun. 13 at 4:15 PM
$LYRA can’t find anything g apart from Zack’s upgrade to buy (rank 2) yesterday
1 · Reply
MrWick007
MrWick007 Jun. 13 at 3:58 PM
$LYRA can anyone explain what this is? Insider buy??
1 · Reply
Akbigd
Akbigd Jun. 13 at 3:53 PM
$LYRA reversal Time, If you are on Robinhood. Turn off Stock lending option and force them to cover
0 · Reply
Stmkr
Stmkr Jun. 13 at 3:52 PM
$LYRA Time for reversal again
0 · Reply
Rjinvestments88
Rjinvestments88 Jun. 13 at 3:17 PM
$LYRA nice to see that big order from insider didn't sell 👍
1 · Reply
MrWick007
MrWick007 Jun. 13 at 2:41 PM
$LYRA dead money?
1 · Reply
Stmkr
Stmkr Jun. 13 at 1:42 PM
$LYRA Lets see if management will take the risk of waiting for FDA feedback before raising
1 · Reply
Rjinvestments88
Rjinvestments88 Jun. 13 at 1:13 PM
$LYRA 👀 this Today looking to jump in
0 · Reply
StockFlips
StockFlips Jun. 12 at 8:21 PM
$LYRA Gapper attempt 🤔
0 · Reply
Drugtrade
Drugtrade Jun. 12 at 6:18 PM
$LYRA slip and slide 😳
0 · Reply
aitana_ortiz
aitana_ortiz Jun. 12 at 4:04 PM
$LYRA $BFAC 🚀 $GEAT is going parabolic - now at $0.0699 (+74.7%) Blink and you’ll miss it👀
0 · Reply
Rjinvestments88
Rjinvestments88 Jun. 12 at 3:30 PM
$LYRA think most are waiting for that offering before buying 🤔
1 · Reply
EsotericDark
EsotericDark Jun. 12 at 9:35 AM
$CLDI Right now it's this, $MRSN and $BDSX. Comfortably in the green on all three right now. Feeling quite good. We'll see how this progresses. Previously held $LYRA from February up until its massive run-up at the start of the month. Profits have been split up between these three positions.
0 · Reply
Tofer85
Tofer85 Jun. 11 at 8:50 PM
$JAGX $LYRA $PLRZ $QNRX $TAOP really 🤦‍♂️
0 · Reply
Akbigd
Akbigd Jun. 11 at 8:38 PM
$LYRA Something Cooking after Hours. 120k shares traded
0 · Reply
Scooter0732
Scooter0732 Jun. 11 at 6:50 PM
$LYRA lets see the gap close a little more and I’ll bite
1 · Reply
BreakoutBetter
BreakoutBetter Jun. 11 at 6:36 PM
$JAGX low float verging breakout $TAOP $LYRA $PLRZ $QNRX rs
0 · Reply
joeycash_
joeycash_ Jun. 11 at 6:22 PM
$LYRA
0 · Reply
Stmkr
Stmkr Jun. 11 at 4:52 PM
$LYRA I hope they don't raise before clarifying the regulatory pathway with FDA.
0 · Reply
SkyYk2
SkyYk2 Jun. 11 at 3:49 PM
$LYRA buying
0 · Reply